Wells Fargo Downgrades Halozyme Therapeutics (HALO) Due to Limited Upside
Wells Fargo has downgraded its rating for Halozyme Therapeutics (HALO, Financial), a U.S. biotechnology company, from "Overweight" to "Equal Weight," with a target price set at $62, indicating limited upside potential. This year, Halozyme's stock has surged by 50%, compared to the S&P 500's approximately 21% rise.
Why Halozyme Therapeutics (HALO) Could Beat Earnings Estimates Again
Halozyme Therapeutics (HALO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Halozyme Therapeutics (HALO) Up 14.8% Since Last Earnings Report: Can It Continue?
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Halozyme Earnings, Guidance Point to Bullish Future
Strong revenue growth and a bright outlook have Halozyme Therapeutics, Inc. (HALO) shares rising.
Halozyme Therapeutics, Inc.: Significantly Undervalued Growth Based On Current Fundamentals
Based on fundamental analysis, Halozyme Therapeutics, Inc. presents high returns on invested capital and returns on equity which will drive returns for investors. HALO is trading at a significant discount to its fundamentals and shows the ability to make good M&A decisions. The company operates a subscription-like business model with strong growth in revenue and royalties from licensing agreements.
Halozyme's (HALO) Q2 Earnings & Sales Top Estimates, Stock Up
Halozyme (HALO) reports better-than-expected second-quarter 2024 results. The company maintains revenue guidance for 2024.
Halozyme Therapeutics, Inc. (HALO) Q2 2024 Earnings Call Transcript
Halozyme Therapeutics, Inc. (NASDAQ:HALO ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Tram Bui - Vice President of Investor Relations and Corporate Communications Helen Torley - President and Chief Executive Officer Nicole LaBrosse - Chief Financial Officer Conference Call Participants Jason Butler - Citizens JMP Cerena Chen - Wells Fargo Jessica Fye - JP Morgan Michael DiFiore - Evercore ISI Mitchell Kapoor - H.C. Wainwright Brendan Smith - TD Cowen Vikram Purohit - Morgan Stanley Joseph Catanzaro - Piper Sandler Operator Good afternoon.
Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Halozyme Therapeutics (HALO) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Beat Estimates
Halozyme Therapeutics (HALO) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.74 per share a year ago.
